404 related articles for article (PubMed ID: 29177953)
1. Phase II Study of Gemcitabine Plus Sirolimus in Previously Treated Patients with Advanced Soft-Tissue Sarcoma: a Spanish Group for Research on Sarcomas (GEIS) Study.
Martin-Liberal J; López-Pousa A; Martínez-Trufero J; Martín-Broto J; Cubedo R; Lavernia J; Redondo A; López-Martín JA; Mulet-Margalef N; Sanjuan X; Tirado ÒM; Garcia-Del-Muro X
Target Oncol; 2018 Feb; 13(1):81-87. PubMed ID: 29177953
[TBL] [Abstract][Full Text] [Related]
2. Randomized phase II study comparing gemcitabine plus dacarbazine versus dacarbazine alone in patients with previously treated soft tissue sarcoma: a Spanish Group for Research on Sarcomas study.
García-Del-Muro X; López-Pousa A; Maurel J; Martín J; Martínez-Trufero J; Casado A; Gómez-España A; Fra J; Cruz J; Poveda A; Meana A; Pericay C; Cubedo R; Rubió J; De Juan A; Laínez N; Carrasco JA; de Andrés R; Buesa JM;
J Clin Oncol; 2011 Jun; 29(18):2528-33. PubMed ID: 21606430
[TBL] [Abstract][Full Text] [Related]
3. Phase II trial of gemcitabine in patients with pretreated advanced soft tissue sarcomas.
Späth-Schwalbe E; Genvresse I; Koschuth A; Dietzmann A; Grunewald R; Possinger K
Anticancer Drugs; 2000 Jun; 11(5):325-9. PubMed ID: 10912948
[TBL] [Abstract][Full Text] [Related]
4. Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial.
Gronchi A; Ferrari S; Quagliuolo V; Broto JM; Pousa AL; Grignani G; Basso U; Blay JY; Tendero O; Beveridge RD; Ferraresi V; Lugowska I; Merlo DF; Fontana V; Marchesi E; Donati DM; Palassini E; Palmerini E; De Sanctis R; Morosi C; Stacchiotti S; Bagué S; Coindre JM; Dei Tos AP; Picci P; Bruzzi P; Casali PG
Lancet Oncol; 2017 Jun; 18(6):812-822. PubMed ID: 28499583
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and toxicity of gemcitabine plus docetaxel combination as a second line therapy for patients with advanced stage soft tissue sarcoma.
Kaya AO; Büyükberber S; Ozkan M; Alkiş N; Sevinc A; Ozdemir NY; Alici S; Esbah O; Berk V; Camci C; Ulas A; Coskun U; Benekli M;
Asian Pac J Cancer Prev; 2012; 13(2):463-7. PubMed ID: 22524807
[TBL] [Abstract][Full Text] [Related]
6. Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial.
Seddon B; Strauss SJ; Whelan J; Leahy M; Woll PJ; Cowie F; Rothermundt C; Wood Z; Benson C; Ali N; Marples M; Veal GJ; Jamieson D; Küver K; Tirabosco R; Forsyth S; Nash S; Dehbi HM; Beare S
Lancet Oncol; 2017 Oct; 18(10):1397-1410. PubMed ID: 28882536
[TBL] [Abstract][Full Text] [Related]
7. A Phase II Study of Gemcitabine, Vincristine, and Cisplatin As Second-Line Treatment for Patients with Advanced Soft Tissue Sarcoma.
Luo Z; Zhang X; Peng W; Wu X; Wang H; Yu H; Wang J; Chang J; Hong X
Medicine (Baltimore); 2015 Oct; 94(43):e1777. PubMed ID: 26512574
[TBL] [Abstract][Full Text] [Related]
8. Phase II trial of gemcitabine as first line chemotherapy in patients with metastatic or unresectable soft tissue sarcoma.
Von Burton G; Rankin C; Zalupski MM; Mills GM; Borden EC; Karen A
Am J Clin Oncol; 2006 Feb; 29(1):59-61. PubMed ID: 16462504
[TBL] [Abstract][Full Text] [Related]
9. [Efficacy and safety of fixed dose rate gemcitabine infusion in combination with docetaxel in patients with relapsed/refractory soft tissue sarcoma].
Yao Z; Yang S; Zhao Y; Yao S; Guo H; Liu Y
Zhonghua Zhong Liu Za Zhi; 2014 Jul; 36(7):541-5. PubMed ID: 25327662
[TBL] [Abstract][Full Text] [Related]
10. Gemcitabine plus sirolimus for relapsed and progressing osteosarcoma patients after standard chemotherapy: a multicenter, single-arm phase II trial of Spanish Group for Research on Sarcoma (GEIS).
Martin-Broto J; Redondo A; Valverde C; Vaz MA; Mora J; Garcia Del Muro X; Gutierrez A; Tous C; Carnero A; Marcilla D; Carranza A; Sancho P; Martinez-Trufero J; Diaz-Beveridge R; Cruz J; Encinas V; Taron M; Moura DS; Luna P; Hindi N; Lopez-Pousa A
Ann Oncol; 2017 Dec; 28(12):2994-2999. PubMed ID: 29045512
[TBL] [Abstract][Full Text] [Related]
11. Phase II trial of gemcitabine in advanced sarcomas.
Okuno S; Edmonson J; Mahoney M; Buckner JC; Frytak S; Galanis E
Cancer; 2002 Jun; 94(12):3225-9. PubMed ID: 12115355
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of gemcitabine plus docetaxel in Japanese patients with unresectable or recurrent bone and soft tissue sarcoma: Results from a single-institutional analysis.
Takahashi M; Komine K; Imai H; Okada Y; Saijo K; Takahashi M; Shirota H; Ohori H; Takahashi S; Chiba N; Mori T; Shimodaira H; Ishioka C
PLoS One; 2017; 12(5):e0176972. PubMed ID: 28489919
[TBL] [Abstract][Full Text] [Related]
13. Phase II study of weekly docetaxel and fixed dose rate gemcitabine in patients with previously treated advanced soft tissue and bone sarcoma.
Lee EM; Rha SY; Lee J; Park KH; Ahn JH
Cancer Chemother Pharmacol; 2012 Mar; 69(3):635-42. PubMed ID: 21959979
[TBL] [Abstract][Full Text] [Related]
14. Feasibility and efficacy of gemcitabine and docetaxel combination chemotherapy for bone and soft tissue sarcomas: multi-institutional retrospective analysis of 134 patients.
Tanaka K; Joyama S; Chuman H; Hiraga H; Morioka H; Yoshikawa H; Hosaka M; Takahashi M; Kubo T; Hatano H; Kaya M; Toguchida J; Nishida Y; Nagano A; Tsumura H; Iwamoto Y
World J Surg Oncol; 2016 Dec; 14(1):306. PubMed ID: 27931230
[TBL] [Abstract][Full Text] [Related]
15. A randomised, open-label, phase II study of neo/adjuvant doxorubicin and ifosfamide versus gemcitabine and docetaxel in patients with localised, high-risk, soft tissue sarcoma.
Davis EJ; Chugh R; Zhao L; Lucas DR; Biermann JS; Zalupski MM; Feng M; Wong SL; Jacobson J; Zyczynski L; Reinke D; Metko G; Baker LH; Schuetze SM
Eur J Cancer; 2015 Sep; 51(13):1794-802. PubMed ID: 26066736
[TBL] [Abstract][Full Text] [Related]
16. A phase II multi-strata study of lurbinectedin as a single agent or in combination with conventional chemotherapy in metastatic and/or unresectable sarcomas.
Cote GM; Choy E; Chen T; Marino-Enriquez A; Morgan J; Merriam P; Thornton K; Wagner AJ; Nathenson MJ; Demetri G; George S
Eur J Cancer; 2020 Feb; 126():21-32. PubMed ID: 31896519
[TBL] [Abstract][Full Text] [Related]
17. A phase II study of gemcitabine and docetaxel combination in relapsed metastatic or unresectable locally advanced synovial sarcoma.
Tansir G; Rastogi S; Kumar A; Barwad A; Mridha AR; Dhamija E; Shamim SA; Bhatnagar S; Bhoriwal S
BMC Cancer; 2023 Jul; 23(1):639. PubMed ID: 37422615
[TBL] [Abstract][Full Text] [Related]
18. A phase 1 and randomized controlled phase 2 trial of the safety and efficacy of the combination of gemcitabine and docetaxel with ontuxizumab (MORAb-004) in metastatic soft-tissue sarcomas.
Jones RL; Chawla SP; Attia S; Schöffski P; Gelderblom H; Chmielowski B; Le Cesne A; Van Tine BA; Trent JC; Patel S; Wagner AJ; Chugh R; Heyburn JW; Weil SC; Wang W; Viele K; Maki RG
Cancer; 2019 Jul; 125(14):2445-2454. PubMed ID: 31034598
[TBL] [Abstract][Full Text] [Related]
19. Phase II trial of gemcitabine in patients with advanced sarcomas (E1797): a trial of the Eastern Cooperative Oncology Group.
Okuno S; Ryan LM; Edmonson JH; Priebat DA; Blum RH
Cancer; 2003 Apr; 97(8):1969-73. PubMed ID: 12673725
[TBL] [Abstract][Full Text] [Related]
20. Combination of trabectedin and gemcitabine for advanced soft tissue sarcomas: results of a phase I dose escalating trial of the German Interdisciplinary Sarcoma Group (GISG).
Kasper B; Reichardt P; Pink D; Sommer M; Mathew M; Rauch G; Hohenberger P
Mar Drugs; 2015 Jan; 13(1):379-88. PubMed ID: 25591040
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]